NeuroVive today announces that the subscription period for warrants of series 2018:1 will begin on Thursday, November 1
Lund, Sweden October 31 2018 – NeuroVive Pharmaceutical AB (publ) (”NeuroVive” or ”the Company”) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces today that the subscription period for the warrants of series 2018:1, issued in connection with the Company’s rights issue which subscription period ended on April 24 2018, will begin on Thursday November 1, 2018. The subscription period will run from Thursday November 1, 2018 until Friday, November 30, 2018. The holder of warrants of series 2018:1 is, for each warrant, entitled to subscribe for one (1) new share in NeuroVive at a subscription price